Skip to content
MarketScale
‹ Back to IndustriesSciences

How to Stop Asteroids From Hitting Earth? NASA to Test a Breakthrough Solution

(Bloomberg) — The Russia incident was a warning. On a winter morning in 2013, a meteor the size of a four-story building screamed across the country, exploding near the city of Chelyabinsk and injuring more than 1,600 people amid widespread property damage. The chunk of rock and iron, which was 60 feet across, served as a…

This story was produced through MarketScale. See how Sciences teams put it to work with Executive Thought Leadership.

By Sciences · AsteroidsNasaSpace Junk
Share
How to Stop Asteroids From Hitting Earth? NASA to Test a Breakthrough Solution

Key takeaways

01

(Bloomberg) — The Russia incident was a warning.

02

On a winter morning in 2013, a meteor the size of a four-story building screamed across the country, exploding near the city of Chelyabinsk and injuring more than 1,600 people amid widespread property damage.

03

The chunk of rock and iron, which was 60 feet across, served as a…

(Bloomberg) — The Russia incident was a warning.

On a winter morning in 2013, a meteor the size of a four-story building screamed across the country, exploding near the city of Chelyabinsk and injuring more than 1,600 people amid widespread property damage.

The chunk of rock and iron, which was 60 feet across, served as a violent reminder that Earth, bombarded daily with tons of space-going debris, periodically intersects with large planet killers—and a significant portion of those remain undocumented.

After years of study and discussion, NASA has launched its first effort to spare Earth the kind of calamity that extinguished the dinosaurs, crashing a space probe into an asteroid to alter its speed and course. The Double Asteroid Redirection Test (DART) lifted off Nov. 23 local time aboard a SpaceX rocket from California and will cruise for 10 months to a binary asteroid system.

The idea is that if humans have adequate time to react—decades of notice being preferable—enough energy can be transferred into a speeding rock to alter its trajectory and make it miss Earth, avoiding catastrophe up to and including an extinction-level event. (Though a popular subject in science fiction, it’s worth noting that NASA’s current toolkit of asteroid-nudging techniques does not include Morgan Freeman, Bruce Willis or nuclear weapons.)

Given the critical nature of the work, it’s “not a stretch to suggest that DART may be one of the most consequential missions ever undertaken by NASA,” Casey Dreier, an analyst with The Planetary Society, wrote in a November memo to members.

“This test is to demonstrate that this technology is mature enough so that it would be ready if an actual asteroid impact threat were detected,” Lindley Johnson, NASA’s planetary defense officer, said at a Nov. 4 news conference.

In September of next year—if all goes as planned—the DART craft will target Dimorphos, the smaller, 530-foot rocky body gravitationally tied to the larger Didymos, which is almost 2,600 feet across. The two rocks travel about 1 kilometer (0.6 mile) apart, and Dimorphos orbits its larger sibling every 11 hours and 55 minutes, “just like clockwork,” Johnson said.

Traveling at about 15,000 mph, the craft, which weighs 1,344 pounds and is 59 feet across, is to collide head-on with Dimorphos to both slow the rock by a fraction of a second and to adjust its orbital period around the larger asteroid by several minutes.

“It’s all about measuring the momentum transfer: How much momentum do we put into the asteroid by hitting it with the spacecraft?” said Andy Cheng, lead investigator for the mission at Johns Hopkins University’s Applied Physics Laboratory, which built and manages the spacecraft.

Didymos was discovered 25 years ago and has been well-analyzed (insofar as asteroids and comets go). Its course isn’t predicted to meet Earth in the future, but its relatively close trajectory gives scientists a good test platform to observe with telescopes from about 6.8 million miles away.

DART will use laser targeting and other high-resolution technologies to autonomously choose its impact point. As it races toward the rock, the craft’s camera will send images back to Earth. A small cube-satellite released from the main craft before impact will also record images from a safe distance. One big unknown: The smaller body’s surface composition and topography, which are too small to ascertain from Earth.

For more than 15 years, NASA has been under Congressional orders to catalog near-Earth objects (NEOs) larger than 140 meters (460 feet), the size at which an asteroid strike would cause enormous devastation. “While no known asteroid larger than 140 meters in size has a significant chance to hit Earth for the next 100 years, less than half of the estimated 25,000 NEOs that are 140 meters and larger in size have been found to date,” according to NASA’s Planetary Defense Coordination Office.

The 2013 Chelyabinsk incident caused Washington to take notice, with funding for planetary defense rising by more than 4,000% to $200 million annually over the past decade, thanks to ample support from both the Obama and Trump administrations, Dreier said.

The challenges for spotting these potential planet killers are daunting, however. Earth-based telescopes are limited in range, objects approaching from the direction of the sun can’t be seen, many asteroids reflect almost zero light, and all travel ludicrously fast—43,000 mph or 12 miles per second, on average.

Moreover, not all are local. In 2017, astronomers spied the first large visitor from outside the solar system, a 400-meter, cigar-shaped oddity called Oumuamua that looped around the sun at a blistering 196,000 mph on its way back out into interstellar space.

NASA plans additional testing of its trajectory-altering techniques once it has data from DART’s destruction at Dimorphos, assuming the mission is successful.

A “gravity tractor” is another idea under active consideration, the concept being to attach a spacecraft to an asteroid to enlarge its mass and slowly change its orbit.

Still, observation is critical to preventing a repeat of the fate that befell the dinosaurs. NASA and other scientists are laboring under last year’s loss of the Arecibo Observatory in Puerto Rico, which played a key role in radar assessments of near-Earth objects, helping researchers to determine their size and orbits. Says Johnson, the earth’s defender at NASA: “The key to planetary defense is finding them well before they are an impact threat.”

(Updates throughout to reflect successful launch.)

More stories like this are available on bloomberg.com

©2021 Bloomberg L.P.

About the author

S
Sciences

Sciences: are you visible to AI?

Before they reach out, Sciences buyers ask AI engines which vendors to trust. See how AI describes your company today, and where competitors show up instead.

Free workspace

You just read one expert. Imagine publishing your whole team.

This article was produced through MarketScale. Create a free workspace and turn your own team's expertise into articles, video, and social posts. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale Studio workspace
One video edit a month, on us
AI writing, editing, and publishing tools
In-platform coaching to learn the system

More Sciences Insights

Biopharma's $300 Billion Problem Is Driving the Biggest M&A Cycle in a Decade

Biopharma's $300 Billion Problem Is Driving the Biggest M&A Cycle in a Decade

The pharmaceutical industry is facing a significant challenge as over $300 billion in branded pharmaceutical revenue is set to lose patent protection by 2030. This revenue gap is driving the largest merger and acquisition cycle seen in a decade, with companies seeking external growth through acquisitions. This shift is impacting the entire life sciences supply chain, prompting strategic changes across the industry.

  • 01Over $300 billion in pharmaceutical revenue is at risk due to patent expirations by 2030.
  • 02Big Pharma is engaging in an aggressive cycle of mergers and acquisitions.
  • 03The acquisitions are reshaping the life sciences supply chain.

Jun 29, 2026

Quotient Sciences launches Phase I study of what it calls the first AI-formulated drug in the clinic

Quotient Sciences launches Phase I study of what it calls the first AI-formulated drug in the clinic

Quotient Sciences has initiated a Phase I clinical study at its UK facility for an oral solid dose formulation designed using artificial intelligence — what the company believes is the first AI-formulated drug to reach human clinical evaluation. The study, cleared by the UK's Medicines and Healthcare products Regulatory Agency, will assess safety and pharmacokinetics in healthy volunteers. The program, which used Intrepid Labs' machine learning algorithm, signals a broader shift in how contract drug development organizations are integrating AI across formulation and clinical workflows.

  • 01Quotient Sciences initiated a Phase I study of an AI-designed oral solid dose formulation at its UK facility following MHRA approval — the first such case the company believes has been reported.
  • 02The formulation was developed using Intrepid Labs' advanced machine learning algorithm in combination with Quotient Sciences' Translational Pharmaceutics platform.
  • 03The milestone is part of a broader CRDMO strategy to embed AI-enabled approaches across formulation development and clinical workflows, with implications for the wider contract pharma sector.

Jun 17, 2026

Quotient Sciences launches Phase I trial of what it calls the first AI-formulated drug to reach the clinic

Quotient Sciences launches Phase I trial of what it calls the first AI-formulated drug to reach the clinic

Quotient Sciences has initiated a Phase I clinical study of an oral solid dose formulation designed using AI, cleared by the UK's MHRA and conducted at the company's UK facility. The trial—built on machine learning algorithms from partner Intrepid Labs and Quotient's Translational Pharmaceutics platform—aims to validate AI as a direct contributor to formulation design rather than just an upstream analytical tool. Benchling characterizes the broader moment as biotech entering a "builder phase," in which leading organizations embed AI capability at the bench level rather than running isolated pilots.

  • 01Quotient Sciences has dosed healthy volunteers in a Phase I study it describes as the first clinical evaluation of an AI-designed oral formulation, following approval from the UK's MHRA.
  • 02The formulation was developed using advanced machine learning algorithms from Intrepid Labs, integrated with Quotient Sciences' Translational Pharmaceutics platform.
  • 03Benchling identifies a sector-wide shift toward embedding AI capability directly at the bench, moving beyond isolated pilots to structural adoption across biotech R&D.

Jun 17, 2026

Explore More Sciences Insights

Read more expert perspectives from across Sciences.

Browse Sciences Hub

About the Expert

S
Sciences

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Sciences and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512